Esfahani Khashayar, Ferrario Cristiano, Le Philippe, Panasci Lawrence
Department of Medical Oncology, Jewish General Hospital, Montreal, Quebec, Canada.
BMJ Case Rep. 2014 Jun 12;2014:bcr2014204287. doi: 10.1136/bcr-2014-204287.
Low malignant potential serous tumours (LMPSTs) of the ovary represent an indolent disease, with an excellent prognosis in a majority of patients. Patients with recurrent LMPSTs tend to develop widespread disease with a mortality rate as high as 70%. These tumours tend to have a very poor response to standard chemotherapy, and the management of primary and recurrent disease beyond surgical resection is not well defined. The majority of LMPST have been reported to express oestrogen and progesterone hormone receptors. However, only three reported cases of antihormonal treatment in this setting, and only one using aromatase inhibitors (AI), have been previously reported. We herein report long-term complete remission of two patients with relapsed, chemotherapy-resistant LMPSTs, treated with long-term AI (anastrozole 1 mg daily) as per negative MRI and positron emission tomography scans. Our results warrant further investigation for the use of AIs for metastatic recurrent LMPSTs.
卵巢低恶性潜能浆液性肿瘤（LMPSTs）是一种惰性疾病，大多数患者预后良好。复发性LMPSTs患者往往会发展为广泛播散性疾病，死亡率高达70%。这些肿瘤对标准化疗的反应往往很差，手术切除以外的原发性和复发性疾病的治疗尚不明确。据报道，大多数LMPSTs表达雌激素和孕激素受体。然而，此前仅有3例关于这种情况下抗激素治疗的报道，且仅有1例使用芳香化酶抑制剂（AI）。我们在此报告了2例复发性、化疗耐药的LMPSTs患者经长期AI（阿那曲唑每日1 mg）治疗后长期完全缓解的情况，根据MRI和正电子发射断层扫描结果均为阴性。我们的结果值得对AI用于转移性复发性LMPSTs进行进一步研究。
